Rezultati pretrage autora

1

Chronic Lung Disease after Premature Birth od Vivek Subbiah

Izdano 2008

Preuzmi cijeli tekst
Carta

Spremi u popis

Spremljeno u:
2

The next generation of evidence-based medicine od Vivek Subbiah

Izdano 2023

Preuzmi cijeli tekst Preuzmi cijeli tekst
Revisão

Spremi u popis

Spremljeno u:
3

Tissue-agnostic cancer therapies: promise, reality, and the path forward od Vivek Subbiah

Izdano 2025

Preuzmi cijeli tekst
Artigo

Spremi u popis

Spremljeno u:
4

Challenging Standard-of-Care Paradigms in the Precision Oncology Era od Vivek Subbiah, Razelle Kurzrock

Izdano 2018

Preuzmi cijeli tekst Preuzmi cijeli tekst
Revisão

Spremi u popis

Spremljeno u:
5

Managing Cancer Care during the COVID-19 Pandemic and Beyond od Omar Alhalabi, Vivek Subbiah

Izdano 2020

Preuzmi cijeli tekst Preuzmi cijeli tekst
Artigo

Spremi u popis

Spremljeno u:
6

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: Genomics Is the Diagnosis od Vivek Subbiah, Razelle Kurzrock

Izdano 2023

Preuzmi cijeli tekst
Artigo

Spremi u popis

Spremljeno u:
7

Tumor-agnostic drug development in dMMR/MSI-H solid tumors od Deepak Bhamidipati, Vivek Subbiah

Izdano 2023

Preuzmi cijeli tekst Preuzmi cijeli tekst
Revisão

Spremi u popis

Spremljeno u:
8

Clinical development and management of adverse events associated with FGFR inhibitors od Vivek Subbiah, Srđan Verstovšek

Izdano 2023

Preuzmi cijeli tekst Preuzmi cijeli tekst
Revisão

Spremi u popis

Spremljeno u:
9

Advances in Targeting RET-Dependent Cancers od Vivek Subbiah, Gilbert J. Cote

Izdano 2020

Preuzmi cijeli tekst
Revisão

Spremi u popis

Spremljeno u:
10

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy od Mohamed A. Gouda, Vivek Subbiah

Izdano 2023

Preuzmi cijeli tekst
Revisão

Spremi u popis

Spremljeno u:
11

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors od Mohamed A. Gouda, Vivek Subbiah

Izdano 2023

Preuzmi cijeli tekst Preuzmi cijeli tekst
Revisão

Spremi u popis

Spremljeno u:
12

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers od Mohamed A. Gouda, Vivek Subbiah

Izdano 2023

Preuzmi cijeli tekst Preuzmi cijeli tekst
Revisão

Spremi u popis

Spremljeno u:
13

Clinical Development of BRAF plus MEK Inhibitor Combinations od Vivek Subbiah, Christina S. Baik, John M. Kirkwood

Izdano 2020

Preuzmi cijeli tekst Preuzmi cijeli tekst
Revisão

Spremi u popis

Spremljeno u:
14

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm od Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Izdano 2020

Preuzmi cijeli tekst Preuzmi cijeli tekst
Revisão

Spremi u popis

Spremljeno u:
15

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives od Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

Izdano 2017

Preuzmi cijeli tekst Preuzmi cijeli tekst
Artigo

Spremi u popis

Spremljeno u:
16

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians od Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

Izdano 2020

Preuzmi cijeli tekst
Editorial

Spremi u popis

Spremljeno u:
17

State-of-the-Art Strategies for Targeting RET-Dependent Cancers od Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

Izdano 2020

Preuzmi cijeli tekst
Revisão

Spremi u popis

Spremljeno u:
18

The abscopal effect in patients with cancer receiving immunotherapy od Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

Izdano 2023

Preuzmi cijeli tekst Preuzmi cijeli tekst
Revisão

Spremi u popis

Spremljeno u:
19

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? od Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

Izdano 2025

Preuzmi cijeli tekst
Revisão

Spremi u popis

Spremljeno u:
20

The emerging role of PI3K inhibitors for solid tumour treatment and beyond od Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

Izdano 2023

Preuzmi cijeli tekst
Revisão

Spremi u popis

Spremljeno u:

Chronic Lung Disease after Premature Birth od Vivek Subbiah

The next generation of evidence-based medicine od Vivek Subbiah

Tissue-agnostic cancer therapies: promise, reality, and the path forward od Vivek Subbiah

Challenging Standard-of-Care Paradigms in the Precision Oncology Era od Vivek Subbiah, Razelle Kurzrock

Managing Cancer Care during the COVID-19 Pandemic and Beyond od Omar Alhalabi, Vivek Subbiah

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: <i>Genomics Is the Diagnosis</i> od Vivek Subbiah, Razelle Kurzrock

Tumor-agnostic drug development in dMMR/MSI-H solid tumors od Deepak Bhamidipati, Vivek Subbiah

Clinical development and management of adverse events associated with FGFR inhibitors od Vivek Subbiah, Srđan Verstovšek

Advances in Targeting RET-Dependent Cancers od Vivek Subbiah, Gilbert J. Cote

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy od Mohamed A. Gouda, Vivek Subbiah

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E–Positive Adult and Pediatric Solid Tumors od Mohamed A. Gouda, Vivek Subbiah

Precision oncology with selective RET inhibitor selpercatinib in <i>RET</i>-rearranged cancers od Mohamed A. Gouda, Vivek Subbiah

Clinical Development of BRAF plus MEK Inhibitor Combinations od Vivek Subbiah, Christina S. Baik, John M. Kirkwood

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm od Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives od Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians od Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers od Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

The abscopal effect in patients with cancer receiving immunotherapy od Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? od Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

The emerging role of PI3K inhibitors for solid tumour treatment and beyond od Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

Rezultati pretrage - Vivek Subbiah

Chronic Lung Disease after Premature Birth od Vivek Subbiah

The next generation of evidence-based medicine od Vivek Subbiah

Tissue-agnostic cancer therapies: promise, reality, and the path forward od Vivek Subbiah

Challenging Standard-of-Care Paradigms in the Precision Oncology Era od Vivek Subbiah, Razelle Kurzrock

Managing Cancer Care during the COVID-19 Pandemic and Beyond od Omar Alhalabi, Vivek Subbiah

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: <i>Genomics Is the Diagnosis</i> od Vivek Subbiah, Razelle Kurzrock

Tumor-agnostic drug development in dMMR/MSI-H solid tumors od Deepak Bhamidipati, Vivek Subbiah

Clinical development and management of adverse events associated with FGFR inhibitors od Vivek Subbiah, Srđan Verstovšek

Advances in Targeting RET-Dependent Cancers od Vivek Subbiah, Gilbert J. Cote

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy od Mohamed A. Gouda, Vivek Subbiah

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E–Positive Adult and Pediatric Solid Tumors od Mohamed A. Gouda, Vivek Subbiah

Precision oncology with selective RET inhibitor selpercatinib in <i>RET</i>-rearranged cancers od Mohamed A. Gouda, Vivek Subbiah

Clinical Development of BRAF plus MEK Inhibitor Combinations od Vivek Subbiah, Christina S. Baik, John M. Kirkwood

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm od Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives od Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians od Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers od Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

The abscopal effect in patients with cancer receiving immunotherapy od Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? od Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

The emerging role of PI3K inhibitors for solid tumour treatment and beyond od Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

Alati za pretragu:

Povezani predmeti